{"id":966268,"date":"2026-05-21T18:29:41","date_gmt":"2026-05-21T22:29:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/optima-trial-results-to-be-presented-at-asco-provide-new-evidence-supporting-prosigna-guided-chemotherapy-decisions-in-breast-cancer\/"},"modified":"2026-05-21T18:29:41","modified_gmt":"2026-05-21T22:29:41","slug":"optima-trial-results-to-be-presented-at-asco-provide-new-evidence-supporting-prosigna-guided-chemotherapy-decisions-in-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/optima-trial-results-to-be-presented-at-asco-provide-new-evidence-supporting-prosigna-guided-chemotherapy-decisions-in-breast-cancer\/","title":{"rendered":"OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer"},"content":{"rendered":"

<\/p>\n

OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer<\/b><\/p>\n

Additional Data from ENZAMET Study Show How Decipher Can Help Metastatic Prostate Cancer Patients Avoid Unnecessary Treatment and Enable More Personalized Care<\/i><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE<\/a>)–Veracyte, Inc.<\/a> (NASDAQ: VCYT), a leading cancer diagnostics company, announced today that data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests will be presented at the 2026 ASCO Annual Meeting in Chicago, taking place May 29 \u2013 June 2. The OPTIMA<\/a> and ENZAMET<\/a> trial presentations are expected to provide practice-changing evidence demonstrating how Veracyte\u2019s genomic tests can guide treatment decisions in both early-stage breast cancer and metastatic prostate cancer.<\/p>\n

\nThe OPTIMA study<\/a> is a prospective, randomized trial led by University College London (UCL) and supported by the National Institute for Health Research (NIHR). The study enrolled more than 4,400 patients and was designed to address a key clinical question: which patients would benefit from chemotherapy, and which may be able to safely avoid it, and its long-term toxicities. The study results demonstrating how the Prosigna test can guide adjuvant chemotherapy decisions in patients with high-risk breast cancer will be presented by Dr. Rob Stein of UCL and OPTIMA Trial Chief Investigator, on Saturday, May 30 during the breast cancer session.<\/p>\n

\n“The OPTIMA trial results represent a major milestone in precision breast oncology and will provide Level 1A evidence supporting Prosigna-guided treatment decisions,” said Kelly Marcom, M.D., Veracyte\u2019s medical director, Breast Cancer. “These findings have the potential to transform how clinicians treat a large population of patients with breast cancer, helping them to personalize their patient\u2019s treatment choices using the genomic insights that the Prosigna test provides.”<\/p>\n

\nThe ENZAMET trial<\/a> is an international, prospective, randomized study conducted by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Dr. Christopher Sweeney of South Australian Immunogenomics Cancer Institute, Adelaide University, will present data on Saturday, May 30 during the Genitourinary Cancer session on Decipher Prostate\u2019s ability to predict treatment benefit with the chemotherapy docetaxel in metastatic, hormone-sensitive prostate cancer. The independent analysis evaluated how the Decipher test can help identify which patients are most likely to benefit from treatment intensification with triplet therapy (docetaxel to standard of cancer hormonal therapy).<\/p>\n

\n“Together, these studies provide practice-changing evidence supporting the use of Veracyte\u2019s tests in guiding treatment decisions across cancer types,” said Phillip Febbo, M.D., Veracyte\u2019s chief scientific and medical officer. “In practice, this means clinicians can more confidently match treatment intensity to individual patient risk, helping ensure the right level of care while avoiding unnecessary treatment and its side effects, for both breast and prostate cancer patients.”<\/p>\n

\nAdditional research to be presented at ASCO supports the company’s mission to transform cancer care for patients all over the world.<\/p>\n

Oral Presentations at ASCO 2026 Annual Meeting<\/span><\/b><\/p>\n